Thanks to the combined work of AIM and the Alzheimer's Association, the federal government has committed to a goal to prevent and effectively treat Alzheimer's disease by 2025. But achieving this goal requires a significant research commitment at the National Institutes of Health (NIH).
AIM has worked with the Alzheimer's Association to propel the U.S. government to rise to this challenge, resulting in a more than six-fold increase in Alzheimer's and dementia research funding since the passage of NAPA — including a historic $425 million increase for Alzheimer's research at the NIH for fiscal year 2019. Today, funding for Alzheimer's and dementia related research at the National Institutes of Health (NIH) is $2.8 billion, following an additional $350 million increase for fiscal year 2020.
As a result of these significant increases, scientists are able to work at a more rapid pace to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments.
Still, more work remains if we are to meet the government’s 2025 goal. AIM and the Alzheimer's Association are calling on Congress to ensure scientists have the resources needed to continue the momentum, by increasing Alzheimer’s and dementia research funding by $354 million in fiscal year 2021.